Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The Orcharrd Study (OMB110928)
Gustaaf W. van Imhoff, Anton Hagenbeek(Amsterdam UMC Location University of Amsterdam), Bronno van der Holt(Erasmus MC), Michinori Ogura(Japanese Red Cross Nagoya Daini Hospital), Kazimierz Kuliczkowski(Kardio-Med Silesia), Steen Lisby(Genmab (Denmark)), Andrew McMillan(Nottingham University Hospitals NHS Trust), Matthew J. Matasar(Rutgers, The State University of New Jersey), Kirit M. Ardeshna(UCL Biomedical Research Centre), Andrew Davies(University Hospital Southampton NHS Foundation Trust), Qiming Liao(Research Triangle Park Foundation), Michael Fennessy(GlaxoSmithKline (United Kingdom)), María Dolores Caballero Barrigón(Instituto de Investigación Biomédica de Salamanca), Won-Seog Kim(Samsung Medical Center), Thomas S. Lin(GlaxoSmithKline (United States)), Jette Soenderskov Goerloev, Xiaonan Hong(Shanghai Medical College of Fudan University), John Radford(Manchester Academic Health Science Centre)
Cited by 25
Related Papers
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Prediction of Survival in Follicular Lymphoma Based on Molecular Features of Tumor-Infiltrating Immune Cells
|New England Journal of Medicine|2004|1.4k